Alcohol, GLP-1s, and Men: The Data Behind the Cravings Drop

The first randomized clinical trial on semaglutide for alcohol use disorder just published. Here's what it found — and why men on GLP-1s are reporting they've lost interest in drinking without trying to.

Published May 1, 2026 · Last verified May 1, 2026

You've probably heard the anecdotes: men start a GLP-1 for weight loss and a few weeks later, their beer after work tastes like nothing. Their Friday night bourbon doesn't call to them anymore. They're not trying to quit — they just stopped caring about alcohol.

For years, this was dismissed as incidental. Maybe they're eating less, so they're drinking less. Maybe it's placebo. But the clinical evidence has now caught up with the anecdotes, and the story is more interesting than "appetite suppression."

The First Randomized Trial: JAMA Psychiatry, February 2025

In February 2025, researchers led by Dr. Christian Hendershot at USC published the first phase 2 randomized, placebo-controlled clinical trial testing semaglutide specifically for alcohol use disorder (AUD). The study, published in JAMA Psychiatry, enrolled 48 adults with AUD who were not seeking treatment — meaning they weren't trying to quit drinking. They received 9 weeks of either low-dose semaglutide (ramping from 0.25mg to 1.0mg) or placebo.

The results were striking across multiple measures:

In the controlled laboratory portion, participants who received semaglutide consumed measurably less alcohol and had lower breath alcohol concentrations than those on placebo. In real-world tracking over the 9-week treatment period, semaglutide significantly reduced drinks per drinking day and weekly craving scores compared to placebo.

An unexpected finding: among participants who also smoked, the semaglutide group showed greater reductions in cigarettes per day — suggesting the effect extends beyond alcohol to reward-seeking behavior more broadly.

Why It Works: It's Not Just Appetite

The mechanism behind GLP-1s and alcohol reduction is distinct from simple appetite suppression. GLP-1 receptors exist in brain regions central to reward processing, including the nucleus accumbens and ventral tegmental area — the same circuits that drive alcohol reinforcement.

Preclinical research (animal models) has demonstrated that GLP-1 receptor agonists reduce voluntary alcohol consumption and weaken alcohol's reinforcing effects. The drugs appear to modulate the dopamine signaling that makes alcohol (and other substances) feel rewarding. You don't decide to stop wanting alcohol — your brain's reward response to it simply diminishes.

This is fundamentally different from existing AUD medications like naltrexone (which blocks opioid receptors) or acamprosate (which stabilizes neurotransmitter activity). GLP-1s act on a separate pathway, which raises the possibility of complementary treatment approaches.

The Observational Data: Larger Scale, Same Direction

Beyond the randomized trial, larger observational studies point in the same direction. A study published in Nature Communications in 2024, analyzing real-world prescription data, found that semaglutide use was associated with a 50–56% reduction in alcohol use disorder incidence within 12 months compared to other anti-obesity medications.

A 2023 Virginia Tech study surveyed GLP-1 users and analyzed social media reports. Among alcohol-related posts from GLP-1 users (n=1,580), 71% described craving reduction, decreased desire to drink, or similar effects. In a controlled survey component, GLP-1 users reported significantly lower alcohol intake, fewer drinks per episode, lower binge drinking odds, and reduced AUDIT scores (a standardized measure of problematic drinking).

What This Means for Men on GLP-1s

Men drink more than women on average, and alcohol use disorder disproportionately affects men. According to CDC data, alcohol-related deaths claim approximately 178,000 lives in the US annually, with men accounting for the majority. If you're a man on a GLP-1 and you've noticed your drinking has declined without conscious effort, that's not weird — it's pharmacological.

Several practical implications worth understanding:

Alcohol tolerance changes. If you're losing weight and your brain's reward response to alcohol is dampened simultaneously, your tolerance will drop faster than expected. Many men on GLP-1s report feeling effects of alcohol much more quickly — which is a safety consideration for anyone who previously calibrated their consumption based on pre-medication tolerance.

Calorie elimination compounds weight loss. A standard beer is 150 calories. Three beers on a Friday night over 50 weeks is roughly 6.5 pounds of body fat per year in caloric surplus alone. If your GLP-1 medication is reducing your alcohol intake by 2–3 drinks per week, that's a meaningful contributor to your weight loss results — but it's also a benefit that most providers aren't discussing or tracking.

Liver health benefits are multiplicative. GLP-1s already show significant liver benefits — the ESSENCE trial demonstrated 63% resolution of fatty liver inflammation with semaglutide. If you're simultaneously reducing alcohol consumption, the combined benefit to liver health is likely substantial, though no study has isolated this combined effect yet.

Should You Talk to Your Provider About This?

Yes. Whether you're noticing reduced cravings (useful to document for your treatment record), experiencing unexpected intoxication at lower consumption levels (a safety issue), or considering reducing or eliminating alcohol as part of your health goals (an opportunity to leverage what the medication is already doing), this is a conversation worth having.

Providers who take a comprehensive approach to metabolic health — rather than a weight-only focus — are more likely to track these effects and adjust your treatment plan accordingly.

Compounded medications are not FDA-approved. Consult your provider about alcohol interactions with any medication.

Compounded medications are not FDA-approved.

What's Coming Next

Phase 3 trials are now underway specifically testing semaglutide for AUD. A Danish trial (NCT05895643) is evaluating 26 weeks of semaglutide combined with cognitive behavioral therapy in 108 participants with both AUD and obesity, with results expected in late 2025 or early 2026. Larger trials are being planned.

If the phase 3 data confirms what the phase 2 trial and observational studies have shown, semaglutide could receive an FDA indication for alcohol use disorder — which would make it one of the few drugs approved for both obesity and a substance use disorder. For the millions of men where weight, alcohol, and metabolic health intersect, that's a significant development worth watching.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content or provider selection.